HK1223097A1 - 杂芳基取代的吡唑 - Google Patents

杂芳基取代的吡唑 Download PDF

Info

Publication number
HK1223097A1
HK1223097A1 HK16111251.3A HK16111251A HK1223097A1 HK 1223097 A1 HK1223097 A1 HK 1223097A1 HK 16111251 A HK16111251 A HK 16111251A HK 1223097 A1 HK1223097 A1 HK 1223097A1
Authority
HK
Hong Kong
Prior art keywords
group
alkyl
hydrogen
compound
formula
Prior art date
Application number
HK16111251.3A
Other languages
English (en)
Chinese (zh)
Inventor
Marion Hitchcock
Anne Mengel
Hans Briem
Jens Geisler
Gerhard Siemeister
Wilhelm Bone
Amaury Ernesto FERNANDEZ-MONTALVAN
Jens SCHRÖDER
Simon Holton
Ursula MÖNNING
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of HK1223097A1 publication Critical patent/HK1223097A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16111251.3A 2013-06-21 2014-06-17 杂芳基取代的吡唑 HK1223097A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13173280.2 2013-06-21
EP13173280 2013-06-21
PCT/EP2014/062694 WO2014202588A1 (en) 2013-06-21 2014-06-17 Heteroaryl substituted pyrazoles

Publications (1)

Publication Number Publication Date
HK1223097A1 true HK1223097A1 (zh) 2017-07-21

Family

ID=48651937

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111251.3A HK1223097A1 (zh) 2013-06-21 2014-06-17 杂芳基取代的吡唑

Country Status (7)

Country Link
US (1) US20160168130A1 (https=)
EP (1) EP3010911A1 (https=)
JP (1) JP2016522232A (https=)
CN (1) CN105452242A (https=)
CA (1) CA2916109A1 (https=)
HK (1) HK1223097A1 (https=)
WO (1) WO2014202588A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
WO2013092512A1 (en) 2011-12-21 2013-06-27 Bayer Intellectual Property Gmbh Substituted benzylpyrazoles
EP2976335A1 (en) * 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
CN105452237A (zh) 2013-06-21 2016-03-30 拜耳制药股份公司 杂芳基取代的吡唑
JP2016525076A (ja) 2013-06-21 2016-08-22 バイエル ファーマ アクチエンゲゼルシャフト 置換されたベンジルピラゾール類
JP2016526540A (ja) * 2013-06-21 2016-09-05 バイエル ファーマ アクチエンゲゼルシャフト 置換ベンジルピラゾール
CA2928998A1 (en) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
JP2016540017A (ja) * 2013-12-11 2016-12-22 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激物質
AR100886A1 (es) 2014-06-17 2016-11-09 Bayer Pharma AG 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
MA39484A (fr) 2014-09-19 2016-03-24 Bayer Pharma AG Indazoles à substituants benzyle utilisés comme inhibiteurs de bub1
AU2016212230B2 (en) 2015-01-28 2019-09-19 Bayer Pharma Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CA2989469A1 (en) 2015-06-17 2016-12-22 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
UY39391A (es) * 2020-08-24 2022-03-31 Adama Makhteshim Ltd Proceso para la preparación de pirazoles sustituidos
IL301532A (en) 2020-09-23 2023-05-01 Scorpion Therapeutics Inc History Pyrrolo[2,3-C]pyridin-4-one is useful in cancer treatment
TW202229282A (zh) 2020-09-30 2022-08-01 美商史考皮恩治療有限公司 治療癌症之方法
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
BR112023006531A2 (pt) 2020-10-09 2023-10-03 Scorpion Therapeutics Inc Inibidores heterocílicos de egfr e/ou her2, para uso no tratamento de câncer
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
CN121909190A (zh) 2023-06-08 2026-04-21 安塔列斯疗法股份有限公司 1,5-二氢-4H-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗
CN121712773A (zh) 2023-06-08 2026-03-20 安塔列斯疗法股份有限公司 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863282B2 (en) * 2003-03-14 2011-01-04 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AR088020A1 (es) * 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc Compuestos heterociclicos como estimuladores de sgc
WO2012139930A1 (en) * 2011-04-11 2012-10-18 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
UA111754C2 (uk) * 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
WO2013092512A1 (en) * 2011-12-21 2013-06-27 Bayer Intellectual Property Gmbh Substituted benzylpyrazoles
CN105452237A (zh) * 2013-06-21 2016-03-30 拜耳制药股份公司 杂芳基取代的吡唑

Also Published As

Publication number Publication date
CA2916109A1 (en) 2014-12-24
EP3010911A1 (en) 2016-04-27
WO2014202588A1 (en) 2014-12-24
US20160168130A1 (en) 2016-06-16
CN105452242A (zh) 2016-03-30
JP2016522232A (ja) 2016-07-28

Similar Documents

Publication Publication Date Title
HK1223097A1 (zh) 杂芳基取代的吡唑
HK1221717A1 (zh) 取代的苄基吡唑
CN104411701B (zh) 作为Bub1抑制剂的用于治疗癌症的取代的环烯并吡唑
US9745285B2 (en) Heteroaryl substituted pyrazoles
JP6141866B2 (ja) 置換ベンジルピラゾール類
HK1223350A1 (zh) 杂芳基取代的吲唑
JP2016526540A (ja) 置換ベンジルピラゾール
HK1218750A1 (zh) 3-杂芳基取代的吲唑
JP2016536311A (ja) ヘテロアリール置換ピラゾール類
HK1222852A1 (zh) 二氨基杂芳基取代的吡唑
HK1217324A1 (zh) 二氨基杂芳基取代的吲唑
HK1226733A1 (en) Heteroaryl substituted pyrazoles